Vanda Pharmaceuticals' HETLIOZ sNDA for Jet Lag Disorder Rejected by FDA After Re-review
VNDA sits 96% above its 52-week low of $3.809.
Summary
Vanda Pharmaceuticals announced that the FDA has again rejected its supplemental New Drug Application (sNDA) for HETLIOZ for the treatment of jet lag disorder, concluding it cannot be approved in its current form.
Key Events · Product Development and Regulatory · VNDA
-
FDA Rejects HETLIOZ sNDA for Jet Lag
Vanda Pharmaceuticals received a letter from the FDA stating that its supplemental New Drug Application (sNDA) for HETLIOZ (tasimelteon) for the treatment of jet lag disorder cannot be approved in its current form following an expedited re-review.
-
Disagreement on Efficacy Evidence
The FDA acknowledged positive efficacy from Vanda's clinical trials but concluded the data did not provide substantial evidence of effectiveness, primarily arguing that controlled phase advance protocols are not sufficiently analogous to actual jet travel conditions.
-
Company Plans to Challenge Decision
Vanda Pharmaceuticals respectfully disagrees with the FDA's interpretation, maintaining that its submitted dataset meets the statutory standard for effectiveness, and is committed to pursuing all appropriate avenues for approval.
-
Follows Prior Court Ruling
This decision comes after the D.C. Circuit in August 2025 set aside a prior FDA refusal for the same sNDA, leading to the collaborative framework agreement for the expedited re-review.
Analysis · VNDA · Life Sciences
The FDA's second rejection of HETLIOZ for jet lag disorder, even after a court had previously set aside an earlier refusal, represents a significant regulatory setback for Vanda Pharmaceuticals. The core disagreement over the validity of simulated jet lag protocols versus actual travel conditions indicates a fundamental hurdle in the approval pathway. While Vanda plans to pursue all appropriate avenues, this decision creates substantial uncertainty for the commercialization of HETLIOZ in this new indication and could lead to prolonged legal or regulatory battles, impacting the company's near-term growth prospects.
At the time of this filing, VNDA was trading at $7.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $504.7M. The 52-week trading range was $3.81 to $9.60. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.